Salmeterol: Difference between revisions
ClaireLewis (talk | contribs) |
(Text replacement - "-->" to "→") |
||
Line 33: | Line 33: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Long-acting beta-2 agonist, stimulates adenyl | *Long-acting beta-2 agonist, stimulates adenyl cyclase→ increased levels of cyclic AMP→ bronchial smooth muscle relaxation | ||
==Comments== | ==Comments== |
Revision as of 19:31, 8 February 2017
Administration
- Type: Beta-2 agonist, bronchodilator
- Dosage Forms:
- Routes of Administration: Inhalation
- Common Trade Names:
Adult Dosing
- 1 oral inhalation (50mcg) q12h
Pediatric Dosing
- >4yo: 1 oral inhalation (50mcg) q12h
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: no adjustment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Severe asthma exacerbation, asthma-related death
- Prolonged QT interval
Common
- Musculoskeletal pain
- Headache
Pharmacology
- Half-life: 5.5h
- Metabolism: Hepatic
- Excretion: Mostly fecal
Mechanism of Action
- Long-acting beta-2 agonist, stimulates adenyl cyclase→ increased levels of cyclic AMP→ bronchial smooth muscle relaxation